Catalog No.
PAB86902
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Panitumumab
Tested applications
ELISA: 1:4000-1:8000
Target
Rabbit polyclonal to Vectibix.
Specificity
The product is specific for Panitumumab. This antibody serves as an excellent positive control for Panitumumabb immunogenicity (ADA) assays.
Concentration
0.5 mg/ml
Purification
Purified by antigen affinity column.
Accession
CAS: 339177-26-3
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Background
Panitumumab with trade name Vectibix, is an FDA-approved drug for the treatment of patients with EGFR-expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens. It is a human monoclonal antibody. Panitumumab binds to the human EGF receptor (EGFR), preventing binding of activating ligands, such as the EGF and transforming growth factor-α. Antibodysystem Anti-Panitumumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Panitumumab.
Evaluation of the usefulness of protocol-based magnesium supplementation for hypomagnesemia in patients with advanced or recurrent colorectal cancer treated with panitumumab., PMID:40366467
Epidermal growth factor receptor antibody and axial elongation in experimental myopia., PMID:40326259
Construction and evaluation of a novel Stx2a-based immunotoxin against epidermal growth factor receptor (EGFR)., PMID:40315796
Response to anti-EGFR therapy in chemo-refractory right-sided RAS wild-type metastatic colorectal cancer: a case report and literature review., PMID:40115908
Background Tissue with Native Target Expression Can Determine Presence of Nodal Metastasis in Head and Neck Squamous Cell Carcinoma Patients Infused with Targeted Fluorescent Tracers., PMID:40100567
Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations., PMID:40097366
The emerging role of Sotorasib plus Panitumumab combination therapy in colorectal cancer treatment., PMID:40080361
Costs of Adverse Event Management Associated with First-Line Cetuximab or Panitumumab in Metastatic Colorectal Cancer Patients in Saudi Arabia., PMID:40061835
Aphthous-Like Stomatitis in a Patient Receiving Panitumumab., PMID:40017685
The Pharmacologic Inhibition of KRAS Mutants as a Treatment for Cancer: Therapeutic Principles and Clinical Results., PMID:40009739
Could Panitumumab with very low dose Capecitabine be an option as a maintenance regimen., PMID:39945465
Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer., PMID:39927885
Using methods to extend inferences to specific target populations to improve the precision of subgroup analyses., PMID:39924128
An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study., PMID:39820673
Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population., PMID:39805350
Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer., PMID:39799855
AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG)., PMID:39779412
Au@109Pd Core-Shell Nanoparticles Conjugated to Panitumumab for the Combined β--Auger Electron Therapy of Triple-Negative Breast Cancer., PMID:39769315
Limited Efficacy of Anti-EGFR Monoclonal Antibodies in Colorectal Cancer Patients with Rare RAS Variants: Analysis of the C-CAT Database., PMID:39727997
[Case of Minocycline-Induced Thrombocytopenia during Chemotherapy for Ascending Colon Cancer]., PMID:39721793
Second-line systemic treatment for metastatic colorectal cancer: A systematic review and Bayesian network meta-analysis based on RCT., PMID:39715232
Prognostic value of radiologic and pathological response in colorectal cancer liver metastases upon systemic induction treatment: subgroup analysis of the CAIRO5 trial., PMID:39667310
Intensified Total Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer: Long-term Results of a Prospective Phase II Study., PMID:39667262
The Use of Fluorescent Markers to Detect and Delineate Head and Neck Cancer: A Scoping Review., PMID:39629534
Anti-EGFR Rechallenge in Metastatic Colorectal Cancer and the Role of ctDNA: A Systematic Review and Meta-analysis., PMID:39623250
SPECT/CT imaging of EGFR-positive head and neck squamous cell carcinoma patient-derived xenografts with 203Pb-PSC-panitumumab in NRG mice., PMID:39589608
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial., PMID:39576946
First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial., PMID:39570583
Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework., PMID:39520611
Concurrent Eruptive Melanocytic Nevi and Multiple Keratoacanthomas Induced by Encorafenib., PMID:39479087
Efficacy and Safety of Anti-EGFR Therapy Rechallenge in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis., PMID:39436445
Immuno-PET Imaging of EGFR with 64Cu-NOTA Panitumumab in Subcutaneous and Metastatic Nonsmall Cell Lung Cancer Xenografts., PMID:39402973
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study., PMID:39356138
Fluidic Interface for Surface-based DNA Origami Studies., PMID:39348886
The tumor cell killing capacity of head and neck cancer patient-derived neutrophils depends on tumor stage, gender and the antibody isotype., PMID:39306937
Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors., PMID:39227409
Measures of Performance and Clinical Superiority Thresholds for 'Test-and-treat' Predictive Biomarkers., PMID:39222295
Hazard Ratios and Alternative Effect Measures: An Applied Illustration., PMID:39212064
Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group., PMID:39210583
Risk Factor Analysis for Anti-epidermal Growth Factor Receptor Monoclonal Antibody-induced Problematic Skin Toxicities in Patients With Liver Metastatic Colorectal Cancer., PMID:39187340
BRAF K601E-mutated metastatic colorectal cancer in response to combination therapy with encorafenib, binimetinib, and cetuximab: A case report., PMID:39072179
Neuronal toxicity of monoclonal antibodies (mAbs): an analysis of post-marketing reports from FDA Adverse Event Reporting System (FAERS) safety database., PMID:39052049
Editorial: Biological therapy for allergic diseases: peculiarities, prospects, and challenges., PMID:39050379
Safety of first-line systemic therapy in patients with metastatic colorectal cancer: a network meta-analysis of randomized controlled trials., PMID:39048944
Real-world cost-effectiveness of panel-based genomic testing to inform therapeutic decisions for metastatic colorectal cancer., PMID:39032558
Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer., PMID:39012279
Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance., PMID:39000238
Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial., PMID:38996519
Sotorasib in KRAS-Mutated Colorectal Cancer. Reply., PMID:38986068
Sotorasib in KRAS-Mutated Colorectal Cancer., PMID:38986067
For research use only. Not for human or drug use.
